Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TROXERUTIN CRS (20 MG)

TROXERUTIN CRS (20 MG)

7085-55-4

DISCOVER
Tylosin phosphate for peak identification 10 mg

Tylosin phosphate for peak identification 10 mg

1401-69-0

DISCOVER
CALCIPOTRIOL (ANHYDROUS) - REFERENCE SPECTRUM (N/A)

CALCIPOTRIOL (ANHYDROUS) - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
ACARBOSE CRS (100 MG)

ACARBOSE CRS (100 MG)

56180-94-0

DISCOVER
TRANDOLAPRIL CRS (10 MG)

TRANDOLAPRIL CRS (10 MG)

87679-37-6

DISCOVER
HUMAN VACCINIA IMMUNOGLOBULINBRP (1 ML)

HUMAN VACCINIA IMMUNOGLOBULINBRP (1 ML)

NA

DISCOVER
ATRACURIUM FOR IMPURITY F IDENTIFICATION CRS (15 MG)

ATRACURIUM FOR IMPURITY F IDENTIFICATION CRS (15 MG)

64228-81-5

DISCOVER
ATRACURIUM FOR PEAK IDENTIFICATION CRS (5 MG)

ATRACURIUM FOR PEAK IDENTIFICATION CRS (5 MG)

64228-81-5

DISCOVER
CEFALOTIN FOR IMPURITY B IDENTIFICATION CRS (10 MG)

CEFALOTIN FOR IMPURITY B IDENTIFICATION CRS (10 MG)

58-71-9

DISCOVER
CEFOTAXIME FOR PEAK IDENTIFICATION CRS (10 MG)

CEFOTAXIME FOR PEAK IDENTIFICATION CRS (10 MG)

64485-93-4

DISCOVER
CHLORPROMAZINE IMPURITY A CRS(15 MG)

CHLORPROMAZINE IMPURITY A CRS(15 MG)

NA

DISCOVER
CHLORPROMAZINE IMPURITY E CRS(10 MG)

CHLORPROMAZINE IMPURITY E CRS(10 MG)

92-39-7

DISCOVER